ACM
IRWD icon

Asymmetry Capital Management’s Ironwood Pharmaceuticals IRWD Stock Holding History

Asymmetry Capital Management’s Portfolio IRWD Stock Details IRWD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-61,405
Closed -$971K – 35
2017
Q2 		$971K Sell
61,405
-36,326
-37% -$528K 1.15% 24
2017
Q1 		$1.4M Buy
97,731
+29,240
+43% +$400K 1.95% 18
2016
Q4 		$877K Buy
+68,491
New +$865K 1.63% 17

Other funds holding IRWD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Asymmetry Capital Management's IRWD Position: Q3 2017 in Review

Asymmetry Capital Management sold out of Ironwood Pharmaceuticals (IRWD) in Q3 2017, closing a stake of 61,405 shares — an estimated $971K sold.

Asymmetry Capital Management first reported a position in IRWD in Q4 2016 and held it in 3 quarters. The position peaked at $1.4M in Q1 2017. 149 funds tracked by Wall St. Rank hold IRWD as of Q3 2017.

  • Asymmetry Capital Management reported no remaining Ironwood Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Asymmetry Capital Management sold 61,405 Ironwood Pharmaceuticals shares in Q3 2017, an estimated $971K.
  • Asymmetry Capital Management first reported a position in Ironwood Pharmaceuticals in Q4 2016 and held it in 3 quarters.
  • Asymmetry Capital Management's Ironwood Pharmaceuticals position peaked at $1.4M in Q1 2017.
  • 149 funds tracked by Wall St. Rank held Ironwood Pharmaceuticals as of Q3 2017.

Based on Asymmetry Capital Management's 13F filing for Q3 2017, filed 3 Nov 2017.